Νέα

Genekor at the San Antonio Breast Cancer Symposium (SABCS) 2024

This year, our team attended the San Antonio Breast Cancer Symposium (SABCS) in Texas, a key event in breast cancer research. It was a great opportunity to connect with healthcare professionals and learn about the latest advancements in the field.

At the symposium, two research abstracts involving Genekor’s scientific team were presented, showcasing valuable insights from Greek breast cancer cohorts:

Poster 2:
„The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients“
Presented by Dr. Ioannis Natsiopoulos, MD, FEBS-BS et al, this study evaluated the prognostic and predictive utility of the Oncotype DX test in patients with ER+/HER2-/pT2N0, cM0 tumors.
Key finding: Among younger patients (≤50 years) with high clinical risk, 45.4% had a RS <16, suggesting they could avoid chemotherapy and benefit from endocrine therapy alone.We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.SABCS_P4_09_29_Poster_VenizelosSABCS_P4_09_29_Poster_VenizelosSABCS_P4-07-30_Poster_NatsiopoulosSABCS_P4-07-30_Poster_NatsiopoulosDownloadDownload

We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.SABCS_P4_09_29_Poster_VenizelosSABCS_P4_09_29_Poster_VenizelosSABCS_P4-07-30_Poster_NatsiopoulosSABCS_P4-07-30_Poster_NatsiopoulosDownloadDownload

We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.